<DOC>
	<DOCNO>NCT02228928</DOCNO>
	<brief_summary>The efficacy safety low concentration [ 0.65 % ( 50 µg/cm2 ) 1.25 % ( 100 µg/cm2 ) ] capsaicin patch compare conventional 0.075 % capsaicin cream placebo patch patient suffer peripheral neuropathy</brief_summary>
	<brief_title>Study Capsaicin Patch Management Peripheral Neuropathic Pain</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<mesh_term>Peripheral Nerve Injuries</mesh_term>
	<mesh_term>Capsaicin</mesh_term>
	<criteria>patient 18 year age old age chronic peripheral neuropathy relate diagnosis either PHN DPN patient chronic peripheral neuropathic pain 3 month 11pointed Numeric Rating Scale ( NRS ) pain score ≥ 4 patient diagnosis PHN eligible least 3 month elapse since shingle vesicle crust patient DPN well control diabetes ask maintain stable dose oral hypoglycemic insulin study period patient take concomitant pain medication anticonvulsant , antidepressant , anxiolytic , opioids include tramadol require maintain stable dose least 4 week study enrollment conservative therapy TENS , physical therapy , chiropractic , massage , biofeedback , yoga stop least 5 week enrollment woman childbearing age require negative pregnancy test willing use effective method contraception least 28 day last exposure study medication diffusely distribute neuropathic pain result spinal stenosis , postoperative origin , complex regional pain syndrome , genetic neurological disease , significant pain outside target area significant pain etiology PHN DNP severe acute chronic medical psychiatric condition , laboratory abnormality may increase risk associate study participation investigational product administration may interfere compliance interpretation study result andin judgment investigator would make subject inappropriate participate study painful PHN area locate face scalp hairline implant medical device treatment neuropathic pain use topically applied agent include capsaicincontaining product , 5 % lidocaine patch similar product , local anesthetic , steroid within past 21 day hypersensitivity know capsaicin ; current use class 1 antiarrhythmic drug ; uncontrolled diabetes mellitus uncontrolled hypertension If patient take oral NSAID COX2 Inhibitor , stop least2 week randomization ; however acetaminophen pain control allow 4g per day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Peripheral Nerve Injury</keyword>
	<keyword>Postherpetic Neuralgia</keyword>
</DOC>